Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 234

1.

Differential expression of Hsp27 in normal oesophagus, Barrett's metaplasia and oesophageal adenocarcinomas.

Soldes OS, Kuick RD, Thompson IA 2nd, Hughes SJ, Orringer MB, Iannettoni MD, Hanash SM, Beer DG.

Br J Cancer. 1999 Feb;79(3-4):595-603.

2.

Differential expression of the MAD2, BUB1 and HSP27 genes in Barrett's oesophagus-their association with aneuploidy and neoplastic progression.

Doak SH, Jenkins GJ, Parry EM, Griffiths AP, Baxter JN, Parry JM.

Mutat Res. 2004 Mar 22;547(1-2):133-44.

PMID:
15013707
3.

Sucrase-isomaltase gene expression in Barrett's esophagus and adenocarcinoma.

Wu GD, Beer DG, Moore JH, Orringer MB, Appelman HD, Traber PG.

Gastroenterology. 1993 Sep;105(3):837-44.

PMID:
8359653
4.

Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.

Lord RV, Brabender J, Wickramasinghe K, DeMeester SR, Holscher A, Schneider PM, Danenberg PV, DeMeester TR.

Surgery. 2005 Nov;138(5):924-31.

PMID:
16291394
5.

Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.

Kimchi ET, Posner MC, Park JO, Darga TE, Kocherginsky M, Karrison T, Hart J, Smith KD, Mezhir JJ, Weichselbaum RR, Khodarev NN.

Cancer Res. 2005 Apr 15;65(8):3146-54.

6.

Barrett's oesophagus: microsatellite analysis provides evidence to support the proposed metaplasia-dysplasia-carcinoma sequence.

Gleeson CM, Sloan JM, McGuigan JA, Ritchie AJ, Weber JL, Russell SE.

Genes Chromosomes Cancer. 1998 Jan;21(1):49-60.

PMID:
9443041
7.

Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence.

Lord RV, Salonga D, Danenberg KD, Peters JH, DeMeester TR, Park JM, Johansson J, Skinner KA, Chandrasoma P, DeMeester SR, Bremner CG, Tsai PI, Danenberg PV.

J Gastrointest Surg. 2000 Mar-Apr;4(2):135-42.

PMID:
10675236
8.

MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma.

Wijnhoven BP, Hussey DJ, Watson DI, Tsykin A, Smith CM, Michael MZ; South Australian Oesophageal Research Group.

Br J Surg. 2010 Jun;97(6):853-61. doi: 10.1002/bjs.7000.

PMID:
20301167
9.

Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.

Zou H, Molina JR, Harrington JJ, Osborn NK, Klatt KK, Romero Y, Burgart LJ, Ahlquist DA.

Int J Cancer. 2005 Sep 10;116(4):584-91.

10.

Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus.

Guillem P, Billeret V, Buisine MP, Flejou JF, Lecomte-Houcke M, Degand P, Aubert JP, Triboulet JP, Porchet N.

Int J Cancer. 2000 Dec 15;88(6):856-61.

11.

Abundant expression of the intestinal protein villin in Barrett's metaplasia and esophageal adenocarcinomas.

Regalado SP, Nambu Y, Iannettoni MD, Orringer MB, Beer DG.

Mol Carcinog. 1998 Jul;22(3):182-9.

PMID:
9688144
12.

Cellular and molecular mechanisms responsible for progression of Barrett's metaplasia to esophageal carcinoma.

Beilstein M, Silberg D.

Gastroenterol Clin North Am. 2002 Jun;31(2):461-79, ix. Review.

PMID:
12134613
13.

Prostaglandin EP2 receptor expression is increased in Barrett's oesophagus and oesophageal adenocarcinoma.

Jiménez P, Piazuelo E, Cebrian C, Ortego J, Strunk M, García-Gonzalez MA, Santander S, Alcedo J, Lanas A.

Aliment Pharmacol Ther. 2010 Feb 1;31(3):440-51. doi: 10.1111/j.1365-2036.2009.04172.x. Epub 2009 Oct 16.

14.

A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus.

Brabender J, Marjoram P, Salonga D, Metzger R, Schneider PM, Park JM, Schneider S, Hölscher AH, Yin J, Meltzer SJ, Danenberg KD, Danenberg PV, Lord RV.

Oncogene. 2004 Jun 10;23(27):4780-8.

PMID:
15107828
15.

Microsatellite analysis provides evidence of neoplastic transformation in long-segment, but not in short-segment, Barrett's oesophagus.

Gleeson CM, McDougall NI, Russell SE, McGuigan JA, Collins JS, Sloan JM.

Int J Cancer. 2000 Feb 15;85(4):482-5.

16.

Increased c-myb mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.

Brabender J, Lord RV, Danenberg KD, Metzger R, Schneider PM, Park JM, Salonga D, Groshen S, Tsao-Wei DD, DeMeester TR, Hölscher AH, Danenberg PV.

J Surg Res. 2001 Aug;99(2):301-6.

PMID:
11469901
17.

Intestinal differentiation and p53 gene alterations in Barrett's esophagus and esophageal adenocarcinoma.

Moore JH, Lesser EJ, Erdody DH, Natale RB, Orringer MB, Beer DG.

Int J Cancer. 1994 Feb 15;56(4):487-93.

PMID:
7906678
18.

Glutathione S-transferase-pi expression is downregulated in patients with Barrett's esophagus and esophageal adenocarcinoma.

Brabender J, Lord RV, Wickramasinghe K, Metzger R, Schneider PM, Park JM, Hölscher AH, DeMeester TR, Danenberg KD, Danenberg PV.

J Gastrointest Surg. 2002 May-Jun;6(3):359-67.

PMID:
12022988
19.

The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma.

Brabender J, Marjoram P, Lord RV, Metzger R, Salonga D, Vallböhmer D, Schäfer H, Danenberg KD, Danenberg PV, Selaru FM, Baldus SE, Hölscher AH, Meltzer SJ, Schneider PM.

Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2113-7.

20.

Telomerase, hTERT and splice variants in Barrett's oesophagus and oesophageal adenocarcinoma.

Barclay JY, Morris A, Nwokolo CU.

Eur J Gastroenterol Hepatol. 2005 Feb;17(2):221-7.

PMID:
15674101
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk